CSL Behring's Andembry can be used to prevent recurrent attacks of hereditary angioedema (HAE) by the NHS, according to finalised guidance from reimbursement authority NICE. The just-published ...
Ionis has won an FDA green light for an RNA-based hereditary angioedema (HAE) treatment, Dawnzera, that can be self-administered by patients every four or eight weeks. The first-in-class drug targets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback